Located in Billingham, UK, the research center, known as BioCampus, will include a 42,000-square-foot office space, which is expected to house approximately 250 of the company’s existing employees, with an additional 50 people to be hired.
The site will have the potential to be expanded in the future with additional R&D laboratories or manufacturing facilities.
The project will see Fujifilm Diosynth Biotechnologies invest up to £14.5m ($17.11m), utilizing funding by the Tees Valley Mayor and Combined Authority, as well as from the UK government’s Local Growth Fund.
By building the new facility, Fujifilm Diosynth expects to meet the growing demand for its portfolio of partner programs, including development and manufacturing services of biologics, vaccines and gene therapies, the company stated.
Paul Found, the company’s chief operating officer, stated that the BioCampus will enable Fujifilm Diosynth to significantly enhance the quality of the working environment for its employees.
Construction of the BioCampus is expected to be completed by March 2021.
